Bionomics shareholders approve re-domiciliation to U.S. via Neuphoria; 96% vote in favor

Neuphoria Therapeutics Inc.

96% of votes cast and 87% of shareholders present voted in favor of scheme to re-domicile from Australia to Delaware.
Supreme Court of New South Wales to consider approval at Dec 16 hearing; conditions include expert opinion unchanged.
Implementation expected on or about Dec 24, 2024; Neuphoria shares to trade on Nasdaq under symbol 'NEUP'.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.